<p>Green nanotechnology leverages biological systems for the sustainable synthesis of nanomaterials, offering an eco-friendly alternative to conventional methods. In this study, we report the phyco-synthesis of silver oxide nanoparticles (AgONPs) using an aqueous extract of&#xa0;<i>Tolypothrix</i>&#xa0;sp. A-8, a cyanobacterium rich in bioactive metabolites that serve as both reducing and capping agents. Synthesis was optimized by controlling key physicochemical parameters (reaction time, precursor concentration, temperature, and pH) to maximize yield. The resulting nanoparticles were comprehensively characterized using X-Ray Diffraction, Ultraviolet Visible Spectroscopy (UV), Fourier Transform Infrared Spectroscopy, Dynamic Light Scattering, Scanning Electron Microscopy, and Energy-Dispersive X-ray Spectroscopy. The AgONPs demonstrated significant anti-leishmanial activity, with IC<sub>50</sub> values of 10.43&#xa0;µg/mL against promastigotes and 32.43&#xa0;µg/mL against amastigotes of&#xa0;<i>Leishmania tropica</i>, and an LD<sub>50</sub> of 45&#xa0;µg/mL against&#xa0;<i>Artemia salina</i>. In anticancer assays against HCT-116 colorectal carcinoma cells, the nanoparticles induced cytotoxicity, with an IC<sub>50</sub> of approximately 8512&#xa0;µg/mL. They also exhibited notable antioxidant potential, with total antioxidant capacity and total reducing power reaching 58.4% and 51.4%, respectively, at 300&#xa0;µg/mL. The AgONPs were highly biocompatible, showing non-hemolytic effects at concentrations up to 200&#xa0;µg/mL (3.2% hemolysis) and an IC<sub>50</sub> of 918.2&#xa0;µg/mL against human macrophages, confirming their non-toxic nature. Anti-inflammatory activity was confirmed via human red blood cell membrane stabilization, with a 62.8% reduction in hemolysis. Furthermore, the nanoparticles demonstrated dose-dependent anti-diabetic potential, achieving 23.3% glucose scavenging at 900&#xa0;µg/mL. Antimicrobial assays revealed potent activity, with minimum inhibitory concentrations of 50&#xa0;µg/mL against&#xa0;<i>Botrytis cinerea</i>,&#xa0;<i>Staphylococcus aureus</i>, and coagulase-negative&#xa0;<i>Staphylococcus</i>, while&#xa0;<i>Bacillus subtilis</i>&#xa0;was the least susceptible bacterial strain (MIC: 150&#xa0;µg/mL). This study pioneers&#xa0;<i>Tolypothrix</i>&#xa0;sp. A-8 as a scalable biofactory for the sustainable production of multifunctional AgONPs. With their potent, quantitative bioactivities and excellent biocompatibility, these nanomaterials hold significant promise for next-generation nanotherapeutics, including applications in wound healing, targeted drug delivery, and the management of leishmaniasis, cancer, inflammation, and diabetes.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Harnessing Tolypothrix sp. A-8 for biogenic synthesis of silver oxide nanoparticles (AgONPs) for multifunctional biomedical applications

  • Muhammad Kaleem,
  • Lubna Anjum Minhas,
  • Amber Jabeen,
  • Muhammad Abdullah,
  • Ghulam Mustafa Bajwa,
  • Hafiz Muhammad Umer Farooqi,
  • Dovran Shamamedov,
  • Abdul Samad Mumtaz

摘要

Green nanotechnology leverages biological systems for the sustainable synthesis of nanomaterials, offering an eco-friendly alternative to conventional methods. In this study, we report the phyco-synthesis of silver oxide nanoparticles (AgONPs) using an aqueous extract of Tolypothrix sp. A-8, a cyanobacterium rich in bioactive metabolites that serve as both reducing and capping agents. Synthesis was optimized by controlling key physicochemical parameters (reaction time, precursor concentration, temperature, and pH) to maximize yield. The resulting nanoparticles were comprehensively characterized using X-Ray Diffraction, Ultraviolet Visible Spectroscopy (UV), Fourier Transform Infrared Spectroscopy, Dynamic Light Scattering, Scanning Electron Microscopy, and Energy-Dispersive X-ray Spectroscopy. The AgONPs demonstrated significant anti-leishmanial activity, with IC50 values of 10.43 µg/mL against promastigotes and 32.43 µg/mL against amastigotes of Leishmania tropica, and an LD50 of 45 µg/mL against Artemia salina. In anticancer assays against HCT-116 colorectal carcinoma cells, the nanoparticles induced cytotoxicity, with an IC50 of approximately 8512 µg/mL. They also exhibited notable antioxidant potential, with total antioxidant capacity and total reducing power reaching 58.4% and 51.4%, respectively, at 300 µg/mL. The AgONPs were highly biocompatible, showing non-hemolytic effects at concentrations up to 200 µg/mL (3.2% hemolysis) and an IC50 of 918.2 µg/mL against human macrophages, confirming their non-toxic nature. Anti-inflammatory activity was confirmed via human red blood cell membrane stabilization, with a 62.8% reduction in hemolysis. Furthermore, the nanoparticles demonstrated dose-dependent anti-diabetic potential, achieving 23.3% glucose scavenging at 900 µg/mL. Antimicrobial assays revealed potent activity, with minimum inhibitory concentrations of 50 µg/mL against Botrytis cinereaStaphylococcus aureus, and coagulase-negative Staphylococcus, while Bacillus subtilis was the least susceptible bacterial strain (MIC: 150 µg/mL). This study pioneers Tolypothrix sp. A-8 as a scalable biofactory for the sustainable production of multifunctional AgONPs. With their potent, quantitative bioactivities and excellent biocompatibility, these nanomaterials hold significant promise for next-generation nanotherapeutics, including applications in wound healing, targeted drug delivery, and the management of leishmaniasis, cancer, inflammation, and diabetes.